@ARTICLE{
author={Tobias Joshua,Kundi Michael,Garner-Spitzer E,Zielinski Christoph,Maglakelidze Marina,Andric Zoran G,Petrovic Z,Nagarkar R,Chawla T,Chong LO,Nixon B,Yavrom S,Ede NJ,Wiedermann Ursula},
year={2023},
title={HERIZON: A phase II study of HER-Vaxx (IMU-131), a HER2targeting peptide vaccine plus standard of care chemotherapy in patients with HER2+advanced stomach cancer - Dose-dependent anti-cancer antibodies correlating with improved clinical outcome},
journal={ANNALS OF ONCOLOGY},
volume={34},
number={},
pages={S864-S864},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Tobias Joshua,Kundi Michael,Garner-Spitzer E,Zielinski Christoph,Maglakelidze Marina,Andric Zoran G,Petrovic Zeljko M,Nagarkar R,Chawla T,Chong LMO,Nixon B,Yavrom S,Ede NJ,Wiedermann Ursula},
year={2023},
title={HERIZON: A phase 2 study of HER-Vaxx (IMU-131), a HER2t-argeting peptide vaccine plus SOC chemotherapy in patients with HER2+advanced stomach cancer - correlation of the antibody responses and clinical outcome},
journal={ANNALS OF ONCOLOGY},
volume={34},
number={},
pages={S4-S4},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Cufer Tanja,Ciuleanu Tudor E,Berzinec Peter,Galffy Gabriela,Jakopovic Marko,Jassem Jacek,Jovanovic Dragana D,Mihaylova Zhasmina,Ostoros Gyula,Thallinger Christiane,Zemanova Milada,Zielinski Christoph},
year={2020},
title={Access to Novel Drugs for Non-Small Cell Lung Cancer in Central and Southeastern Europe: A Central European Cooperative Oncology Group Analysis},
journal={ONCOLOGIST},
volume={25},
number={3},
pages={E598-E601},
document_type={Article},
} 

@ARTICLE{
author={Wilking Nils,Bucsics Anna,Kandolf-Sekulovic Lidija O,Kobelt Gisela,Laslop Andrea,Makaroff Lydia,Roediger Alexander,Zielinski Christoph},
year={2019},
title={Achieving equal and timely access to innovative anticancer drugs in the European Union (EU): summary of a multidisciplinary CECOG-driven roundtable discussion with a focus on Eastern and South-Eastern EU countries},
journal={ESMO OPEN},
volume={4},
number={6},
pages={-},
document_type={Review},
} 

@ARTICLE{
author={Wilking Nils,Bucsics Anna,Kandolf-Sekulovic Lidija O,Kobelt Gisela,Laslop Andrea,Makaroff Lydia,Roediger Alexander,Zielinski Christoph},
year={2019},
title={Achieving equal and timely access to innovative anticancer drugs in the European Union (EU): summary of a multidisciplinary CECOG-driven roundtable discussion with a focus on Eastern and South-Eastern EU countries},
journal={ESMO OPEN},
volume={4},
number={6},
pages={-},
document_type={Review},
} 

@ARTICLE{
author={Ryska Ales,Buiga Rares,Fakirova Albena,Kern Izidor,Olszewski Wlodzimierz,Plank Lukas,Seiwerth Sven,Toth Erika,Eri Zivka,Thallinger Christiane,Zielinski Christoph,Brcic Luka},
year={2018},
title={Non-Small Cell Lung Cancer in Countries of Central and Southeastern Europe: Diagnostic Procedures and Treatment Reimbursement Surveyed by the Central European Cooperative Oncology Group},
journal={ONCOLOGIST},
volume={23},
number={12},
pages={E152-E158},
document_type={Article},
} 

@ARTICLE{
author={Brodowicz Thomas,Ciuleanu Tudor E,Radosavljevic Davorin Z,Shacham-Shmueli Einat,Vrbanec Damir,Plate Signe,Mrsic-Krmpotic Zrinka,Dank M,Purkalne Gunta,Messinger D,Zielinski Christoph},
year={2013},
title={FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG study},
journal={ANNALS OF ONCOLOGY},
volume={24},
number={7},
pages={1769-1777},
document_type={Article},
} 

@ARTICLE{
author={Ciuleanu Tudor E,Nikolic Vladimir,Shmueli E,Vrbanec Damir,Plate Signe,Mrsic-Krmpotic Zrinka,Dank M,Purkalne Gunta,Brodowicz Thomas,Zielinski Christoph},
year={2011},
title={Cetuximab weekly (q1w) versus every two weeks (q2w) plus FOLFOX4 as first-line therapy in patients (pts) with KRAS wild-type (wt) metastatic colorectal cancer (mCRC)},
journal={JOURNAL OF CLINICAL ONCOLOGY},
volume={29},
number={15},
pages={-},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Ciuleanu Tudor E,Nikolic Vladimir,Shmueli E,Vrbanec Damir,Plate Signe,Mrsic-Krmpotic Zrinka,Dank Magdolna,Purkalne Gunta,Brodowicz Thomas,Zielinski Christoph},
year={2011},
title={Cetuximab weekly (q1w) versus every two weeks (q2w) plus FOLFOX4 as first-line therapy in patients (pts) with KRAS wild-type (wt) metastatic colorectal cancer (mCRC).},
journal={JOURNAL OF CLINICAL ONCOLOGY},
volume={29},
number={4},
pages={-},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Ciuleanu Tudor E,Nikolic Vladimir,Shacham-Shmueli Einat,Vrbanec Damir,Plate Signe,Mrsic-Krmpotic Zrinka,Kahan Zsuzsanna,Purkalne Gunta,Brodowicz Thomas,Zielinski Christoph},
year={2011},
title={Cetuximab Weekly (Q1W) Versus Every Two Weeks (Q2W) Plus Folfox4 as First-line Therapy in Patients (PTS) with Kras Wild-Type (WT) Metastatic Colorectal Cancer (MCRC)},
journal={ANNALS OF ONCOLOGY},
volume={22},
number={},
pages={v22-v22},
document_type={Meeting Abstract},
}